Co-Target(s) Information
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T22274 | Target Info | |||
| Target Name | Histone deacetylase 6 (HDAC6) | ||||
| Synonyms |
KIAA0901; JM21; HD6
Click to Show/Hide
|
||||
| Target Type | Clinical trial Target | ||||
| Gene Name | HDAC6 | ||||
| Biochemical Class | Carbon-nitrogen hydrolase | ||||
| UniProt ID | |||||
| Co-Targets of This Target | Top | |||||
|---|---|---|---|---|---|---|
| Co-Target Name | Histone deacetylase 1 (HDAC1) | Successful Target | ||||
| UniProt ID | HDAC1_HUMAN | |||||
| Gene Name | HDAC1 | |||||
| Synonyms |
RPD3L1; HD1
Click to Show/Hide
|
|||||
| Representative Drug(s) | Citarinostat | Drug Info | IC50 = 35 nM | Click to Show More | [1] | |
| 2 | Rocilinostat | Drug Info | IC50 = 38 nM | [2] | ||
| Co-Target Name | Histone deacetylase 2 (HDAC2) | Clinical trial Target | ||||
| UniProt ID | HDAC2_HUMAN | |||||
| Gene Name | HDAC2 | |||||
| Synonyms |
HD2
Click to Show/Hide
|
|||||
| Representative Drug(s) | Rocilinostat | Drug Info | IC50 = 48 nM | Click to Show More | [3] | |
| 2 | Citarinostat | Drug Info | IC50 = 318 nM | [4] | ||
| Co-Target Name | Histone deacetylase 3 (HDAC3) | Clinical trial Target | ||||
| UniProt ID | HDAC3_HUMAN | |||||
| Gene Name | HDAC3 | |||||
| Synonyms |
SMAP45; RPD32; RPD3-2; HD3
Click to Show/Hide
|
|||||
| Representative Drug(s) | Rocilinostat | Drug Info | IC50 = 51 nM | [3] | ||
| Co-Target Name | Histone deacetylase 4 (HDAC4) | Clinical trial Target | ||||
| UniProt ID | HDAC4_HUMAN | |||||
| Gene Name | HDAC4 | |||||
| Synonyms |
KIAA0288; HD4
Click to Show/Hide
|
|||||
| Representative Drug(s) | Rocilinostat | Drug Info | IC50 ~ 1000 nM | Click to Show More | [4] | |
| 2 | Citarinostat | Drug Info | IC50 ~ 1000 nM | [4] | ||
| Co-Target Name | Histone deacetylase 8 (HDAC8) | Patented-recorded Target | ||||
| UniProt ID | HDAC8_HUMAN | |||||
| Gene Name | HDAC8 | |||||
| Synonyms |
Histone deacetylase-8; HDACL1; HD8; CDA07
Click to Show/Hide
|
|||||
| Representative Drug(s) | Rocilinostat | Drug Info | IC50 = 100 nM | [3] | ||
| Co-Target Name | Histone deacetylase 10 (HDAC10) | Patented-recorded Target | ||||
| UniProt ID | HDA10_HUMAN | |||||
| Gene Name | HDAC10 | |||||
| Synonyms |
Polyamine deacetylase HDAC10; HD10
Click to Show/Hide
|
|||||
| Representative Drug(s) | Rocilinostat | Drug Info | IC50 = 125.89 nM | [5] | ||
| Co-Target Name | Histone deacetylase 3-Nuclear receptor corepressor 2 complex (HDAC3-NCOR2) | Co-Target | ||||
| UniProt ID | HDAC3_HUMAN-NCOR2_HUMAN | |||||
| Gene Name | HDAC3-NCOR2 | |||||
| Representative Drug(s) | Rocilinostat | Drug Info | IC50 = 37 nM | [6] | ||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models. J Med Chem. 2019 Sep 26;62(18):8557-8577. | ||||
| REF 2 | Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer. J Med Chem. 2016 Feb 25;59(4):1455-70. | ||||
| REF 3 | Development and therapeutic implications of selective histone deacetylase 6 inhibitors. J Med Chem. 2013 Aug 22;56(16):6297-313. | ||||
| REF 4 | Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia. ACS Med Chem Lett. 2019 Dec 13;11(1):56-64. | ||||
| REF 5 | Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated. J Med Chem. 2019 May 9;62(9):4426-4443. | ||||
| REF 6 | Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif. Bioorg Med Chem. 2018 May 1;26(8):1418-25. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.